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High-dose therapy with autologous bone marrow (ABMT) or
peripheral blood stem cell (PBSC) support is increasingly used in
the treatment of patients with poor prognosis Hodgkin’s disease
(Jagannath et al, 1989; Wheeler et al, 1990; Reece et al, 1991;
Chopra et al, 1993; Linch et al, 1993). Initial studies largely
focused on the treatment of patients with primary refractory or
multiply relapsed Hodgkin’s disease, but, as this modality of
therapy became more widely accepted, it has frequently been used
at the time of first relapse. In some centres, patients deemed to be
at high risk of relapse are being transplanted in first remission
(Carella et al, 1991).
Concern about the increased use of high-dose therapy has
recently been raised, however, by a number of reports containing
details of patients with Hodgkin’s disease and non-Hodgkin’s
lymphoma who have developed myelodysplasia (MDS) or acute
myeloid leukaemia (AML) after autologous transplantation
(Marrolleau et al, 1993; Darrington et al, 1994; Miller et al, 1994;
Stone et al, 1994). Most of these studies have not included patients
with uniform diagnoses and comparisons with similar patients not
receiving high-dose therapy have not been made. This latter
point is of great importance as secondary leukaemia is a well
documented complication of standard dose chemotherapy for
lymphoma, especially Hodgkin’s disease (Tucker et al, 1988;
Devereux et al, 1990; Swerdlow et al, 1993). A number of risk
factors have been identified in the literature. The most important
is the use of combination chemotherapy regimens containing
alkylating agents (e.g. MOPP: mustine, vincristine, procarbazine,
prednisolone), and the cumulative total dose of such drugs
(Pedersen-Bjergaard et al, 1987; Devereux et al, 1990).
Maintenance treatment with chlorambucil (Glicksman et al, 1982),
or lomustine (CCNU) (Devereux et al, 1990) are associated with a
particularly high risk of secondary leukaemia. Other factors identi-
fied in some, but not all, series include the use of combined
modality therapy, advanced age and stage at diagnosis, and
previous splenectomy. There may also be an increased risk
intrinsic to Hodgkin’s disease itself as sporadic cases occurring
in patients untreated for Hodgkin’s disease have been reported
(Lacher and Susman, 1963).
Previously we have attempted a matched pair analysis of
Hodgkin’s patients who have undergone high-dose therapy with
the BEAM (BCNU (carmustine), Etoposide, Ara-C (cytarabine)
and Melphalan) regimen and stem cell transplantation with
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Summary Hodgkin’s disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial
therapy. High-dose therapy with autologous stem cell support has become the standard salvage therapy for patients failing chemotherapy, but
there have been reports of a high incidence of myelodysplasia/acute myeloid leukaemia (MDS/AML) following such treatment. Patients who
receive such therapy form a selected group, however, who have already been subjected to other leukaemogenic factors, such as treatment
with alkylating agents. In order to ascertain the true risk of MDS/AML, comparison must be made with other patients subjected to the same
risks but not undergoing transplantation. We report a retrospective comparative study of 4576 patients with Hodgkin’s disease from the BNLI
and UCLH Hodgkin’s databases, which includes 595 patients who have received a transplant. Statistical analysis including Cox’s proportional
hazards multivariate regression model with time-dependent covariates was employed. This analysis reveals that the risk of developing
MDS/AML was dominated by three factors, namely quantity of prior therapy (relative risk [RR] 2.01, 95% confidence intervals [CI] 1.49–2.71,
for each treatment block, P < 0.0001) and whether the patient had been exposed to MOPP (RR 3.61, 95% CI 1.64–7.95, P = 0.0009) or
lomustine chemotherapy (RR 4.53, 95% CI 1.96–10.44, P = 0.001). Following adjustment for these factors in the multivariate model the
relative risk associated with transplantation was 1.83 (95% CI 0.66–5.11, P = 0.25). This study provides no evidence of a significantly
increased risk of MDS/AML associated with BEAM therapy and autologous transplantation in Hodgkin’s disease. Concern over MDS/AML
should not mitigate against the timely use of this treatment modality. © 1999 Cancer Research Campaign
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non-transplanted patients for factors known to increase the risk of
secondary myeloid malignancy (Harrison et al, 1996). This
suggested that there was no significant increase in risk of
MDS/AML with BEAM but the confidence limits were large and
the study was limited by the highly selected nature of the trans-
plant patients causing difficulty in identifying suitable controls,
even from a large Hodgkin’s disease database.
In the current study we have therefore retrospectively analysed
a larger cohort of 4576 patients with Hodgkin’s disease of whom
595 had received high-dose therapy and an autologous bone
marrow or peripheral blood stem cell transplant. The incidence of
MDS/AML was determined in the series as a whole and after a
transplant procedure. The factors increasing the risk of developing
a secondary myeloid malignancy were identified and using sophis-
ticated statistical modelling to account for time and accrual of
risk factors we have been able to distinguish between the
leukaemogenic effects of the high-dose chemotherapy and other
factors such as previous and alternative conventional dose therapies.
PATIENTS AND METHODS
Patients
This analysis was performed upon 4576 patients with Hodgkin’s
disease composed of 4347 patients registered on the British
National Lymphoma Investigation (BNLI) database, and an addi-
tional 229 sequential patients, not previously registered with the
BNLI who were treated with BEAM chemotherapy and ABMT or
PBSCT at UCLH between September 1983 and May 1995. A total
of 595 patients were transplanted, 336 at UCLH. The BNLI is a
long-established, large clinical collaborative trials group with
follow-up of patients documented on a 6-monthly basis for the
Table 1 Characteristics of all 4576 patients with Hodgkin’s disease and of 595 patients with Hodgkin’s disease who received a transplant
All patients Transplant patients
n % n %
Sex M 2824 (61.7%) 386 (64.9%)
F 1752 (38.3%) 209 (35.1%)
Age at diagnosis 0–15 74 (1.6) 20 (3.4)
(years) 16–25 1442 (31.5) 239 (40.2)
26–35 1237 (27) 218 (36.6)
36–45 719 (15.7) 92 (15.5)
46–55 499 (10.9) 25 (4.2)
56–65 411 (9) 1 (0.1)
66–75 177 (3.9)
76–85 17 (0.4)
mean 35.09 years, mean 27.85 years,
SD 14.87 (range 7–80 years) SD 8.57 (range 7–56 years)
Stage ? 6 (0.2) 4 (0.7)
1 963 (21.0) 41 (6.9)
2 1561 (34.1) 207 (34.8)
3 1196 (26.1) 202 (33.9)
4 850 (18.6) 141 (23.7)
B symptoms ? 10 (0.2) 4 (0.7)
Y 1818 (39.7) 243 (40.8)
N 2748 (60.1) 348 (58.5)
Splenectomy Y 1263 (27.6) 55 (9.2)
N 3313 (72.4) 540 (90.8)
Treatment blocks 1 2336 (51) 1 (0.1)
2 1115 (24.4) 135 (22.7)
3 680 (14.9) 232 (39.0)
4 356 (7.8) 154 (25.9)
>5 89 (1.9) 73 (12.3)
MOPP Y 1139 (24.9) 146 (24.5)
N 3437 (75.1) 449 (75.5)
CCNU Y 147 (3.2) 16 (2.7)
N 4429 (96.8) 579 (97.3)
ABMT conditioning BEAM  582 (97.8)
Other 13 (2.2)
Source of stem cells BM  366 (61.5)
PBSC 208 (35)
Both 11 (1.8)
? 10 (1.7)
Of the 13 patients who received other conditioning a sole patient received each of NAM (neomycin, adriamycin and melphalan), allogeneic
transplant, cyclophosphamide/TBI, melphalan alone, and a single patient received cyclophosphamide, BCNU and vincristine, two patients
received BEM (BCNU, etoposide and melphalan), and two patients were conditioned with melphalan and etoposide. In four patients the
conditioning regime was unknown. Nine patients underwent two transplantation procedures. Abbreviations: BM = bone marrow, PBSC =
peripheral blood stem cells including CD34+ selected cells.478 CN Harrison et al
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first 5 years from diagnosis and at yearly intervals thereafter,
unless relapse occurs, in which case follow-up reverts to the more
frequent schedule. Similar regular updating is performed on the
UCLH transplant database. The proportion of patients on the
BNLI database lost to follow-up is approximately 2% (Swerdlow
et al, 1993), and of the 336 UCLH transplanted patients only four
have been lost to follow-up, three of whom reside permanently
overseas.
Criteria for transplantation at UCLH and within the BNLI trials
were until recently as previously described (Khwaja et al, 1992;
Chopra et al, 1993; Linch et al, 1993). They were:
1. A poor prognosis disease failing to achieve a remission on
MOPP-like chemotherapy
2. failure to achieve complete remission or relapsing within 1
year of an initial alternating regimen (e.g. LOPP/EVAP: chlor-
ambucil, vincristine, procarbazine, prednisolone/etoposide,
vinblastine, doxorubicin, and prednisolone)
3. those patients who had failed on two or more lines of
chemotherapy.
More recently some patients have been transplanted after
relapsing beyond 1 year after obtaining a complete remission (CR)
on alternating therapy. Only one patient in this series was trans-
planted in first CR.
Since number and type of treatment received are important
predictors of the outcome that we were assessing (secondary
MDS/AML), all treatments given over the 28 years of patient
accrual were included in the analysis. Information was available
on a total of 8500 treatment ‘blocks’. Table 1 contains clinical
details pertaining to the 4576 patients on the combined database
and the 595 who underwent transplantation respectively.
High-dose therapy regimen
Altogether 582 (98%) of the transplanted patients received
BEAM. The BEAM regimen has been previously described and
contains BCNU (carmustine) 300 mg m–2 day 1, etoposide
200 mg m–2 days 2–5, Ara-c (cytarabine) 200 mg m–2 twice daily
on days 2–5 and melphalan 140 mg m–2 on day 6. During the time
of this study various doses of etoposide were used as part of a dose
escalation study at UCLH (Mills et al, 1995), six patients received
100 mg m–2, 277 received 200 mg m–2, one received 300 mg m–2,
41 had 400 mg m–2 and 11 had 600 mg m–2. A further 13 patients
received other high-dose chemotherapy regimens and two received
regimens containing total body irradiation.
As a source of stem cells 366 (61.5%) of the transplanted
patients received ABMT, 208 (35%) PBSC (including six CD34+
selected transplants), and 11 (1.8%) ABMT and PBSC. In ten
(1.7%) patients the source of stem cells is unclear.
METHODS
For the purposes of the analysis the patients’ treatment was analysed
as an individual block so, for example, a patient who was initially
treated with mantle radiation then relapsed and was given six
courses of LOPP/EVAP would have been subject to two treatment
Table 2 Factors considered in the univariate analysis
Variable c2 P-value Relative risk 95% CI
Number of treatments 44.52 < 0.001 2.62 2.02–3.41
MOPP chemotherapy 29.96 < 0.001 7.05 3.36–14.83
CCNU therapy 30.49 < 0.001 16.04 7.47–34.45
Alkylating agent 26.31 < 0.001 21.87 2.99–159.9
Transplant 12.17 0.0005 5.35 2.38–12.00
Gender 2.98 0.0842 1.81 0.92–3.55
Age at each block 2.49 0.1148 1.02 1.00–1.04
Year of diagnosis 0.36 0.5485 1.02 0.96–1.08
Age at diagnosis 0.34 0.5579 1.02 1.00–1.05
Splenectomy 0.08 0.7803 1.04 0.51–2.12
Relative risk depends upon the number of categories for that variable, e.g. relative risk for number of treatments relates to adjacent treatment thus comparing
one block versus four blocks the relative risk is 2.623 or 18.
Table 3 Factors considered in the multivariate analysis
Variable c2 P-value Relative risk 95% CI
Significant variables entered into the multivariate model
Number of treatments 18.58 < 0.0001 2.01 1.49–2.71
MOPP chemotherapy 11.09 0.0009 3.61 1.64–7.95
CCNU therapy 10.38 0.0013 4.53 1.96–10.44
Other non-significant variables considered
Gender 4.47 0.0345 2.08 1.06–4.09
Year of diagnosis 3.83 0.0503 1.07 1.00–1.15
Age at each block 3.75 0.0528 1.03 1.00–1.05
Alkylating agent 3.21 0.0732 4.97 0.61–40.78
Age at diagnosis 2.92 0.0875 1.02 1.00–1.05
Transplant 1.30 0.2542 1.83 0.66–5.11
Splenectomy 0.01 0.9203 1.04 0.51–2.12Risk of MDS/AML after BEAM in Hodgkin’s disease 479
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blocks first the radiotherapy, and secondly the LOPP/EVAP
chemotherapy. Each ‘block’ of treatment was considered as a poten-
tial contributing factor to the development of MDS/AML, in terms
of the treatment given in that block, the number of blocks already
given, the age at the start of that block, and the time since the first
treatment for Hodgkin’s disease. To simplify graphical presentation
of these results the times between the start of each block and either
the end of that block, occurrence of AML, or death were calculated
for each block. Occurrence of MDS/AML was considered an event,
the other two end points were considered censored. These event
times were then plotted and analysed using actuarial methods. The
Figures shown therefore demonstrate the incidence of MDS/AML
from the time of diagnosis or the start of a new treatment block.
Thus for the purposes of the graphs which plot incidence of
MDS/AML from the start of each treatment block, if the patient is
receiving, or has received, the treatment under consideration by the
start of that block, their MDS/AML risk is assumed to be related to
that treatment. As an example, consider a patient received radio-
therapy for early-stage disease, relapsed 5 years later and was given
MOPP, relapsed again 4 years after this and received a transplant,
relapsed again 3 years later and received LOPP/EVAP, and finally
contracted AML 2 years after this. There are four treatment blocks
for this patient. When comparing MOPP versus other treatments, the
first block (5 years) will be considered in the ‘other’ category, and
the last three blocks (4, 3 and 2 years respectively) will be included
in the MOPP group. When comparing transplants versus other treat-
ments, the first two treatment blocks will be considered in the
‘other’ category, and the last two will be included in the transplant
group. The first three times will be censored, since the patient did
not get MDS/AML up to that time. The last time will be complete.
A multivariate approach was then employed to investigate
whether the incidence of MDS/AML in the transplanted patients
was different from that in the non-transplanted patients, allowing
for other significant predictors. Some of these predictors were
already known (e.g. the number of previous treatment blocks, prior
use of CCNU) others were checked specifically for this analysis
because of information from previous reports or a priori
reasoning. The complete list of factors considered is given in
Tables 2 and 3.
Statistical analysis
Actuarial incidence rates of MDS/AML were calculated using the
method of Kaplan and Meier (1958) with significance determined
using the log-rank test (Peto et al, 1977).
Incidence rates adjusted for other factors, along with adjusted
log-rank statistics, were calculated using the method described by
Gregory (1988). Thus, for example, the incidence of MDS/AML
in transplants versus non-transplants can be plotted as it would
have looked if there had been an equal proportion of patients
Table 4 Characteristics of 35 patients with Hodgkin’s disease who developed MDS/AML
n %
Sex Male 17 (48.6%)
Female 18 (51.4)
Age at diagnosis of 16–25 16 (45.7)
Hodgkin’s disease 26–35 5 (14.3)
36–45 5 (14.3)
46–55 2 (5.7)
56–65 5 (14.3)
66–75 2 (5.7)
mean 35.11 years, SD 17.09, (range 16–72 years)
Stage 1 2 (5.7)
2 14 (40.0)
3 12 (34.3)
4 7 (20)
B symptoms  Y 16 (45.7)
N 19 (54.3)
Splenectomy Y 15 (42.9)
N 20 (57.1)
Treatment blocks 1 9 (25.75)
2 7 (20.0)
3 9 (25.75)
4 6 (17.1)
>5 4 (11.4)
MOPP Y 24 (68.6)
N 11 (31.4)
CCNU Y 9 (25.7)
N 26 (74.3)
BEAM Y 8 (22.9)
N 27 (77.1)
Stem cell source in ABMT 5 (62.5)
BEAM recipients PBSC 2 (25)
Both 1 (12.5)
A single patient was excluded from the subsequent analysis as the diagnosis of MDS was made at the
same time as that of the original Hodgkin’s disease.480 CN Harrison et al
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having each number of prior treatments in the two groups (trans-
plants and non-transplants). This comparison is actually shown in
Figure 3.
Cox’s proportional hazards multivariate regression model with
time-dependent covariates (Cox, 1972) was used to investigate
whether a transplant at any time increased the risk of MDS/AML.
Other time-dependent covariates such as the administration of
MOPP chemotherapy were also included in the model. Year of
treatment was included to ensure that changes in patient manage-
ment over the long periods of evaluation was not a relevant factor.
A forward step-wise method was used to choose significant
variables, with a cut-off P-value of 0.01. This value was chosen
because of the large number of factors considered in the analysis.
RESULTS
Thirty-five patients developed MDS/AML from the total cohort of
4576, and clinical details pertaining to these patients are shown in
Table 4. In one case the diagnosis of MDS was made at the same
time as that of Hodgkin’s disease, and the MDS was thus consid-
ered to be a co-existing condition in this patient and could not be
therapy related. This patient was therefore censored from further
analyses.
A relatively high proportion (22.9%) of the patients who devel-
oped MDS/AML had undergone transplantation as part of the treat-
ment for their Hodgkin’s disease, whereas the proportion of patients
in this total series who had received high-dose therapy was 13%. The
actuarial incidence of MDS/AML in the 595 patients whom received
a transplant was 0.25%, 1.9% and 9.0% at 5, 10 and 20 years respec-
tively from the time of diagnosis. In the 595 transplanted patients the
actuarial incidence from the time of transplant was 3.1% at 5 years
(95% CI 1.5–6.3%). In the untransplanted patients the actuarial inci-
dence of MDS/AML from the time of diagnosis was 0.4%, 0.8% and
1.3% at 5, 10 and 20 years respectively from the time of diagnosis.
This unadjusted difference in the actuarial incidence of MDS/AML
from the time of diagnosis between transplanted and non-trans-
planted patients is significant and is shown in Figure 1. Of the
patients who had an autograft and developed MDS/AML, all eight
had BEAM conditioning and five received ABMT alone, two PBSC
and one both sources of stem cells.
It is also notable that compared to the patient group as a whole a
much higher proportion of patients developing MDS/AML had
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Figure 1 The cumulative incidence of MDS/AML from the time of diagnosis
in 595 patients with Hodgkin’s disease undergoing transplantation, and 3981
patients who did not undergo transplantation
Figure 2 The cumulative incidence of MDS/AML in transplant and non-
transplant patients shown since the start of each treatment block. There are
747 transplant treatment blocks representing 595 transplants, and 152 blocks
of post-transplant treatment
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Figure 3 The cumulative incidence of MDS/AML in transplant and non-
transplant patients shown since the start of each treatment block and
adjusted for factors identified from the multivariate analysis. There are 747
transplant treatment blocks representing 595 transplants, and 152 blocks of
post-transplant treatment
Figure 4 The influence of number of treatment blocks upon the cumulative
incidence of MDS/AML in 4576 Hodgkin’s disease patients shown since the
start of each treatment blockRisk of MDS/AML after BEAM in Hodgkin’s disease 481
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received MOPP (68.6% (MDS/AML) vs 24.9% for the total 4576
patients who had received MOPP), or CCNU chemotherapy
(25.7% (MDS/AML) vs 3.2%). Furthermore, 54.3% of the
patients developing MDS/AML had received three or more treat-
ment blocks compared to 24.6% of the total group (see Tables 1
and 4). Similarly, the patients who received a transplant were also
different from the total series of 4576 patients with Hodgkin’s
disease with 24.5% and 2.7% receiving MOPP chemotherapy and
CCNU chemotherapy respectively, and 77.2% having three or
more treatment blocks. Importantly, each of these factors has
previously been demonstrated to result in a significantly increased
risk of secondary myeloid malignancy in Hodgkin’s disease.
Therefore a Cox’s proportional hazards multivariate regression
model with time-dependent covariates including the use of trans-
plants, MOPP and CCNU was utilized to investigate whether a
transplant at any time increased the risk of MDS/AML indepen-
dently of other such risk factors.
Factors considered in the univariate analysis (taken from the
Cox model without any covariates in order to make it as compar-
able as possible with the multivariate analysis), the P-value
assigned to them, and their relative risk are shown in Table 2.
The multivariate model with time dependent variates was
employed to assess the influence of transplantation on risk of
MDS/AML. The factors analysed and the results of the multi-
variate analysis are shown in Table 3. Transplantation is not asso-
ciated with a significant risk of secondary myeloid malignancy,
P = 0.25, relative risk 1.83 (95% CI 0.66–5.11). The change from
transplant being highly significant in the univariate analysis to
being not significant in the multivariate analysis occurred immedi-
ately upon the inclusion of ‘number of treatment blocks’ in the
Cox model.
To show this result graphically the risk of MDS/AML in the 595
patients who received a transplant was adjusted for the number of
treatment blocks given and plotted from the start of each treatment
block as detailed in the Methods section (Figures 2 and 3). For the
transplant patients the number of treatment blocks is 747,
reflecting the transplant and any subsequent treatment blocks.
There was no significant difference in incidence of MDS/AML in
the transplanted and non-transplanted groups after this adjustment
was made.
Risk factors for the development of MDS/AML identified from
the multivariate analysis are therefore number of treatment
attempts or blocks, use of MOPP chemotherapy and CCNU
chemotherapy. The effects of these three factors can be seen in
Figures 4, 5 and 6 with relative risks of 2.01 (95% CI 1.49–2.71)
for each treatment block, 3.61 (95% CI 1.64–7.95) for the use of
MOPP and 4.53 (95% CI 1.96–10.44) for the use of CCNU.
None of the other variables remained significant. It is note-
worthy that there was no apparent increased risk associated with
the use of alkylating agents, but this is probably because of the
increased risk ascribed to MOPP as well as the number of treat-
ment blocks. It was clear in the multivariate analysis that MOPP
chemotherapy was a considerably more significant risk factor than
alkylating agent therapy, even though they are correlated. To
demonstrate this point after inclusion of the number of treatment
blocks the c2 and P-values for MOPP and alkylating agents were
14.25 P = 0.0002 and 7.83 P = 0.005 respectively.
DISCUSSION
In this total series of 4576 patients the actuarial incidence of
MDS/AML was 0.4% and 0.9% at 5 and 10 years respectively,
which is similar to the incidence reported from previous studies of
the BNLI data base (Devereux et al, 1990; Swerdlow et al, 1993)
despite the inclusion of an additional cohort of 229 transplanted
patients from the UCLH transplant database. The incidence of
secondary MDS/AML is undoubtedly increased in the cohort of
Hodgkin’s disease patients undergoing high-dose therapy and
autologous transplantation compared to those patients who did not
receive high-dose therapy. This is in accord with reports from
several other series of lymphoma patients in which there is a
projected cumulative incidence of MDS/AML at 5 years post-
high-dose therapy of 6–24% (Marrolleau et al, 1993; Darrington et
al, 1994; Miller et al, 1994; Stone et al, 1994, Traweek et al, 1994).
Specifically, among Hodgkin’s disease patients in the Nebraska
series the risk in those patients still alive at 5 years was estimated
at 11% (Darrington et al, 1994) and in the Minneapolis series 15%
(Miller et al, 1994). These incidences are higher than in the UK
series reported here, where the incidence at 5 years from trans-
plantation was 3.1% (95% CI 1.5–6.3%).
It is possible that the apparent difference in incidence rates
between our own study and those of other groups relates to patient
selection for high-dose therapy procedures or possibly to the
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specific high-dose therapy regimen. The large majority of patients
in our series were conditioned with BEAM chemotherapy (98%)
with very few receiving total body irradiation (0.3%), and in the
Nebraska series the use of TBI was identified as increasing the risk
of secondary MDS/AML (Darrington et al, 1994). The diagnosis
of MDS may be difficult in the post-transplant period as the possi-
bility of disordered haematopoietic reconstitution may itself give
rise to dysplastic features. In such cases it is the practice at UCLH
to carry out cytogenetic examination of the bone marrow and X-
linked chromosome inactivation patterns in females to search for
clonal abnormalities (Gale et al, 1996). However, as the natural
history of therapy related or secondary MDS is usually one of
rapid evolution to bone marrow failure or frank leukaemia
(Devereux, 1991), delayed rather than mistaken diagnosis is a
more likely occurrence.
The crucial issue is whether the occurrence of MDS/AML post-
transplantation is due to the high-dose therapy per se or is merely
indicative of the fact that the transplanted patients have an
increased risk due to their previous, often extensive, therapy.
Secondary MDS/AML in Hodgkin’s disease is a very well
described phenomenon and analyses of its occurrence, natural
history and aetiology have been reported from many institutions
(Tucker et al, 1988; Devereux et al, 1990; Pedersen-Bjergaard and
Larsen, 1982; Pedersen-Bjergaard et al, 1987). Pre-eminent
amongst risk factors identified are the use of combination
chemotherapy regimes containing alkylating agents (e.g. MOPP),
and compounding risk with successive number of attempts at treat-
ment, particularly when that number exceeds two (Devereux et al,
1990). In this series 99.9% of the transplanted patients received
two or more, and 77.2% three or greater treatment blocks of
therapy, so a high risk of developing MDS/AML is inevitable.
Previous studies have been unable to distinguish between the
effects of high-dose therapy and previous therapy as the transplant
series have been restricted to patients who received that modality of
treatment. There has been circumstantial evidence that pre-trans-
plant therapy is the most significant aetiological factor in that the
majority of patients who develop MDS/AML have had multiple
treatment attempts prior to high-dose therapy and chronically
abused stem cells are most likely to undergo malignant transforma-
tion (Devereux et al, 1990). In addition, MDS/AML rarely occurs
after allogeneic transplantation, and although mixed chimaeras do
occasionally occur, this suggests that it is the infused marrow, not
exposed to the high-dose therapy, rather than residual marrow that
is involved in the leukaemogenic process (Stone, 1994).
A Danish series of 76 patients with both non-Hodgkin’s and
Hodgkin’s lymphoma patients receiving BEAM and autologous
stem cell support compared the cumulative risk of MDS/AML in
patients with Hodgkin’s disease following increasing doses of
alkylating agents and demonstrated a similar cumulative risk as
from the time of first chemotherapy (Pedersen-Bjergaard et al,
1997). This study indirectly inferred that therapy with BEAM and
stem cell support might not increase the risk of leukaemogenesis to
any major degree. The case–control study we previously reported
(Harrison et al, 1996) also suggested that treatment prior to trans-
plantation was the major contributor to the myeloid malignancies
described in the post-transplant period, but the analysis was
restricted by the highly selected nature of transplant patients which
limited the ability to identify suitable controls.
A case–control study (Andre et al, 1998) has been reported
which matched Hodgkin’s disease patients treated with a transplant
to three untransplanted controls for the following variables age at
original diagnosis of Hodgkin’s disease, gender, stage, B symptoms
and length of follow-up but not the quantity of prior treatment. In
this study the 5-year cumulative incidence of MDS/AML in the
transplanted patients was 4.3% (95% CI 1.9–9.3%), and the
case–control analysis indicated that there was no significant
increase in risk of MDS/AML following transplantation P = 0.056,
relative risk 2.54 (95% CI 0.98–6.61). This study therefore also
supports the large analysis reported here, even though controls were
not selected according to their prior treatment.
In the current retrospective analysis we have been able to study
4576 patients with Hodgkin’s disease from the BNLI registry and
UCLH transplant database who have detailed clinical and treat-
ment records and well documented follow-up. In this series the
majority of patients who developed MDS/AML post-transplanta-
tion had received ABMT. No conclusions can be drawn about the
relative risks of patients receiving PBSC or ABMT, as the number
of events is small and the follow-up of the PBSC recipients is
markedly less than in the ABMT recipients. A comparison of the
actuarial incidence of secondary myeloid malignancy in trans-
planted versus non-transplanted patients reveals an apparent
increase in risk in the transplanted cohort. Closer examination of
the information, however, combined with sophisticated statistical
modelling demonstrated that the risk of MDS/AML was domi-
nated by three factors, namely quantity of prior therapy and
whether the patient had been exposed to MOPP chemotherapy or
CCNU chemotherapy. It is important to note that the relative risk
with number of treatments of 2.62 (2.02–3.41) applies to each
block of therapy, and in multiply treated patients this becomes a
major risk factor. Thus, for instance, the relative risk comparing
one block versus four blocks is 2.623 or 18. These factors should
clearly be taken into account in all future analysis of the risks of
secondary myeloid malignancy in Hodgkin’s disease, and for the
first time it has been possible to show here that, once the influence
of these risk factors was taken into account, there was no signifi-
cantly increased risk attributable to the high-dose BEAM
chemotherapy. It is not possible to say that there is absolutely no
leukaemogenic effect of BEAM therapy, but merely there is no
evidence of such an effect despite this very large study. Anxieties
about leukaemogenesis should not therefore preclude the early use
of such therapy which could reduce the use of more leukaemo-
genic alternative regimens.
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